Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04934930 | Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status(FLMRD) | unknown | Phase 2 | 40 | Meir Medical CenterOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04917250 | GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma | unknown | Phase 2 | 15 | Beijing Tongren HospitalOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04762485 | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04899414 | Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma | unknown | Phase 2 | 50 | Peking UniversityOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04899427 | Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | unknown | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04899453 | Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04899570 | Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04897477 | Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT03670173 | Safety and Efficacy Assessments of Osalmid in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Shanghai 10th People's HospitalOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04891744 | Selinexor in Combination With Thalidomide and Dexamethasone in RRMM | unknown | Phase 1 / Phase 2 | 48 | Li ZhengOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT02689869 | Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma(Alternative) | unknown | Phase 2 | 98 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04334993 | Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | unknown | Phase 2 | 110 | Israeli Medical AssociationOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04873440 | An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT04860674 | A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma | unknown | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 0 | Apr 27, 2021 | clinicaltrials |
| NCT03795597 | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)(BuMelCarAuto) | unknown | Phase 1 / Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04842487 | R2-CHOP in Untreated DEL-DLBCL:An Open-lable,Multicenter,Phase II Study | unknown | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2021 | clinicaltrials |
| NCT02194751 | Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma | unknown | Phase 2 | 30 | XEME Biopharma Inc.INDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04831710 | Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL | unknown | Phase 2 | 83 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT04827004 | A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03245905 | Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04797182 | Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma | unknown | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04052659 | Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL | unknown | Phase 2 | 30 | Peking UniversityOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT03502629 | Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) | unknown | Phase 2 | 86 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03639181 | Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) | unknown | Phase 2 | 53 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04762745 | The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03949062 | Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL | unknown | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04747093 | Induced-T Cell Like NK Cells for B Cell Malignancies | unknown | Phase 1 / Phase 2 | 12 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT03262298 | Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies | unknown | Phase 1 / Phase 2 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04740203 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03265106 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 20 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04431089 | Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma | unknown | Phase 2 | 122 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2021 | clinicaltrials |
| NCT04723901 | Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04723914 | Dual Target CAR-T Cells in B-cell Lymphoma(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | YuLiOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04707079 | A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma | unknown | Phase 2 | 24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04705090 | A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | unknown | Phase 2 | 90 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jan 12, 2021 | clinicaltrials |
| NCT04688983 | Study in Adult Ph-positive ALL(EWALL-Ph-03) | unknown | Phase 2 | 180 | Cardiff UniversityOTHER | 0 | Dec 30, 2020 | clinicaltrials |
| NCT04676789 | Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL(SPENT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04659434 | Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL | unknown | Phase 2 | 51 | Qian WenbinOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04025593 | Biomarker Guided Treatment in DLBCL | unknown | Phase 2 | 128 | Ruijin HospitalOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04622579 | Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years(R2DLBCL80) | unknown | Phase 2 | 20 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04615468 | A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL) | unknown | Phase 2 | 78 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 4, 2020 | clinicaltrials |
| NCT02772198 | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 300 | Sheba Medical CenterOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT01965977 | Bortezomib Maintenance in High Risk DLBCL(Borma) | unknown | Phase 2 | 59 | Samsung Medical CenterOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT04600947 | Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | unknown | Phase 2 | 69 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 22, 2021source: clinicaltrials